Osteoprotegerin (OPG) and related proteins (RANK, RANKL and TRAIL) in thyroid disease

World Journal of Surgery

Volumn 35, Issue 9, 2011, Pages 1984-1992

  Sood, Sumit K ^a   Balasubramanian, Sabapathy ^a   Higham, Sue ^a   Fernando, Malee ^b   Harrison, Barney ^b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; TNFSF10 PROTEIN, HUMAN; TUMOR MARKER; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER STAGING; COMPARATIVE STUDY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; NEEDLE BIOPSY; NONPARAMETRIC TEST; OBSERVER VARIATION; PATHOLOGY; RETROSPECTIVE STUDY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; THYROID DISEASE; THYROID TUMOR; THYROIDECTOMY; WESTERN BLOTTING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOPSY, NEEDLE; BLOTTING, WESTERN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM STAGING; OBSERVER VARIATION; OSTEOPROTEGERIN; RANK LIGAND; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; STATISTICS, NONPARAMETRIC; THYROID DISEASES; THYROID NEOPLASMS; THYROIDECTOMY; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 80052269567     PISSN: 03642313     EISSN: 14322323     Source Type: Journal    
DOI: 10.1007/s00268-011-1185-5     Document Type: Article

References (42)

1. S Theoleyre Y Wittrant SK Tat, et al. 2004 The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling Cytokine Growth Factor Rev 15 457 475 15561602 10.1016/j.cytogfr. 2004.06.004 1:CAS:528:DC%2BD2cXhtVSlurbI (Pubitemid 39550455)
2. N Udagawa N Takahashi H Yasuda, et al. 2000 Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function Endocrinology 141 3478 3484 10965921 10.1210/en.141.9.3478 1:CAS:528: DC%2BD3cXmtVert7k%3D (Pubitemid 32269038)
3. WS Simonet DL Lacey CR Dunstan, et al. 1997 Osteoprotegerin: a novel secreted protein involved in the regulation of bone density Cell 89 309 319 9108485 10.1016/S0092-8674(00)80209-3 1:CAS:528:DyaK2sXislCgtLc%3D (Pubitemid 27199902)
4. N Bucay I Sarosi CR Dunstan, et al. 1998 Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification Genes Dev 12 1260 1268 9573043 10.1101/gad.12.9.1260 1:CAS:528:DyaK1cXjtVejsrs%3D (Pubitemid 28213402)
5. H Yasuda N Shima N Nakagawa, et al. 1998 Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro Endocrinology 139 1329 1337 9492069 10.1210/en.139.3.1329 (Pubitemid 28510154)
6. DM Anderson E Maraskovsky WL Billingsley, et al. 1997 A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function Nature 390 175 179 9367155 10.1038/36593 1:CAS:528:DyaK2sXnsVOgurY%3D (Pubitemid 27507987)
7. J Li I Sarosi XQ Yan, et al. 2000 RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism Proc Natl Acad Sci USA 97 1566 1571 10677500 10.1073/pnas.97.4.1566 1:CAS:528:DC%2BD3cXhsFCrsL4%3D (Pubitemid 30118482)
8. DL Lacey E Timms HL Tan, et al. 1998 Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation Cell 93 165 176 9568710 10.1016/S0092-8674(00)81569-X 1:CAS:528:DyaK1cXivVyhtrg%3D (Pubitemid 28180851)
9. T Ikeda M Kasai M Utsuyama, et al. 2001 Determination of three isoforms of the receptor activator of nuclear factor-kappaB ligand and their differential expression in bone and thymus Endocrinology 142 1419 1426 11250921 10.1210/en.142.4.1419 1:CAS:528:DC%2BD3MXitlemtb4%3D (Pubitemid 32299669)
10. BR Wong R Josien Y Choi 1999 TRANCE is a TNF family member that regulates dendritic cell and osteoclast function J Leukoc Biol 65 715 724 10380891 1:CAS:528:DyaK1MXktVCisb4%3D (Pubitemid 29279518)
11. SR Wiley K Schooley PJ Smolak, et al. 1995 Identification and characterization of a new member of the TNF family that induces apoptosis Immunity 3 673 682 8777713 10.1016/1074-7613(95)90057-8 1:CAS:528: DyaK28XhtF2iug%3D%3D (Pubitemid 26091143)
12. E Grimaud L Soubigou S Couillaud, et al. 2003 Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis Am J Pathol 163 2021 2031 14578201 10.1016/S0002-9440(10) 63560-2 1:CAS:528:DC%2BD3sXpsVWlur8%3D (Pubitemid 37310032)
13. E Terpos R Szydlo JF Apperley, et al. 2003 Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index Blood 102 1064 1069 12689925 10.1182/blood-2003-02-0380 1:CAS:528:DC%2BD3sXlvFCmt7Y%3D (Pubitemid 36917805)
14. PP Geusens RB Landewe P Garnero, et al. 2006 The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction Arthritis Rheum 54 1772 1777 16736519 10.1002/art.21896 1:CAS:528:DC%2BD28Xms1Sjtbw%3D (Pubitemid 43877926)
15. S Morony C Capparelli I Sarosi, et al. 2001 Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis Cancer Res 61 4432 4436 11389072 1:CAS:528:DC%2BD3MXktlWjsrs%3D (Pubitemid 32685771)
16. I Holen SS Cross HL Neville-Webbe, et al. 2005 Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo: a role in tumour cell survival? Breast Cancer Res Treat 92 207 215 16155791 10.1007/s10549-005-2419-8 1:CAS:528:DC%2BD2MXpvV2gs7c%3D (Pubitemid 41279631)
17. I Holen PI Croucher FC Hamdy, et al. 2002 Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells Cancer Res 62 1619 1623 11912131 1:CAS:528:DC%2BD38XisVSisLw%3D (Pubitemid 34408480)
18. I Pettersen W Bakkelund B Smedsrod, et al. 2005 Osteoprotegerin is expressed in colon carcinoma cells Anticancer Res 25 3809 3816 16309167 1:CAS:528:DC%2BD2MXht12itrnM (Pubitemid 41665149)
19. P Reid I Holen 2009 Pathophysiological roles of osteoprotegerin (OPG) Eur J Cell Biol 88 1 17 18707795 10.1016/j.ejcb.2008.06.004 1:CAS:528: DC%2BD1MXhvFGhu7w%3D
20. SS Cross Z Yang NJ Brown, et al. 2006 Osteoprotegerin (OPG): a potential new role in the regulation of endothelial cell phenotype and tumour angiogenesis? Int J Cancer 118 1901 1908 16287088 10.1002/ijc.21606 1:CAS:528:DC%2BD28Xjt1Gqtbw%3D
21. JL Scoffiled BJ Harrison CL Eaton 2004 Osteoprotegerin is a survival factor for thyroid cancer cells in vitro Br J Surg 91 377 387 10.1002/bjs.4567
22. J Zhang J Dai Y Qi, et al. 2001 Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone J Clin Invest 107 1235 1244 11375413 10.1172/JCI11685 1:CAS:528: DC%2BD3MXjsl2ntr0%3D (Pubitemid 32494540)
23. R Yorke A Younes M Chirala, et al. 2003 Receptor activator of nuclear factor kappaB (RANK) is expressed as a late event during malignant progression in Barrett's metaplasia Eur J Cancer 39 2099 2102 12957466 10.1016/S0959- 8049(03)00434-9 1:CAS:528:DC%2BD3sXmvVKgt7o%3D (Pubitemid 37297768)
24. DH Jones T Nakashima OH Sanchez, et al. 2006 Regulation of cancer cell migration and bone metastasis by RANKL Nature 440 692 696 16572175 10.1038/nature04524 1:CAS:528:DC%2BD28XivFWgtb8%3D
25. SJ Bakewell P Nestor S Prasad, et al. 2003 Platelet and osteoclast beta3 integrins are critical for bone metastasis Proc Natl Acad Sci USA 100 14205 14210 14612570 10.1073/pnas.2234372100 1:CAS:528:DC%2BD3sXpsFGitbc%3D (Pubitemid 37499215)
26. JM Blair Y Zheng CR Dunstan 2007 RANK ligand Int J Biochem Cell Biol 39 1077 1081 17174136 10.1016/j.biocel.2006.11.008 1:CAS:528:DC%2BD2sXmtVejtb0%3D (Pubitemid 46819130)
27. YM Kim YM Lee HS Kim, et al. 2002 TNF-related activation-induced cytokine (TRANCE) induces angiogenesis through the activation of Src and phospholipase C (PLC) in human endothelial cells J Biol Chem 277 6799 6805 11741951 10.1074/jbc.M109434200 1:CAS:528:DC%2BD38XitV2mtrc%3D (Pubitemid 34953061)
28. HH Kim HS Shin HJ Kwak, et al. 2003 RANKL regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway FASEB J 17 2163 2165 14500543 1:CAS:528: DC%2BD3sXovFOhtrc%3D
29. A Ashkenazi RC Pai S Fong, et al. 1999 Safety and antitumor activity of recombinant soluble Apo2 ligand J Clin Invest 104 155 162 10411544 10.1172/JCI6926 1:CAS:528:DyaK1MXkslSmsbw%3D
30. E Cretney K Takeda H Yagita, et al. 2002 Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice J Immunol 168 1356 1361 11801676 1:CAS:528: DC%2BD38XpsFektw%3D%3D (Pubitemid 34094506)
31. HL Neville-Webbe NA Cross CL Eaton, et al. 2004 Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis Breast Cancer Res Treat 86 269 279 15567943 10.1023/B:BREA.0000036900.48763.b3 1:CAS:528:DC%2BD2cXmt1Kqtro%3D (Pubitemid 39070969)
32. CM Shipman PI Croucher 2003 Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells Cancer Res 63 912 916 12615702 1:CAS:528:DC%2BD3sXhs1agtb0%3D (Pubitemid 36278418)
33. MF Heymann A Riet B Le Goff, et al. 2008 OPG, RANK and RANK ligand expression in thyroid lesions Regul Pept 148 46 53 18367263 10.1016/j.regpep. 2008.02.004 1:CAS:528:DC%2BD1cXmsFKhtrk%3D
34. K Mori B Le Goff M Berreur, et al. 2007 Human osteosarcoma cells express functional receptor activator of nuclear factor-kappa B J Pathol 211 555 562 17323424 10.1002/path.2140 1:CAS:528:DC%2BD2sXltFOqu7k%3D (Pubitemid 46502432)
35. SY Lin K Makino W Xia, et al. 2001 Nuclear localization of EGF receptor and its potential new role as a transcription factor Nat Cell Biol 3 802 808 11533659 10.1038/ncb0901-802 1:CAS:528:DC%2BD3MXmvF2ls74%3D (Pubitemid 32842685)
36. H Peng J Myers X Fang, et al. 2002 Integrative nuclear FGFR1 signaling (INFS) pathway mediates activation of the tyrosine hydroxylase gene by angiotensin II, depolarization and protein kinase C J Neurochem 81 506 524 12065659 10.1046/j.1471-4159.2002.00833.x 1:CAS:528:DC%2BD38XjsFGkt78%3D (Pubitemid 34809329)
37. XD Zhang AV Franco T Nguyen, et al. 2000 Differential localization and regulation of death and decoy receptors for TNF-related apoptosis-inducing ligand (TRAIL) in human melanoma cells J Immunol 164 3961 3970 10754286 1:CAS:528:DC%2BD3cXis1Wlur4%3D (Pubitemid 30215048)
38. YC Lin-Lee LV Pham AT Tamayo, et al. 2006 Nuclear localization in the biology of the CD40 receptor in normal and neoplastic human B lymphocytes J Biol Chem 281 18878 18887 16644731 10.1074/jbc.M513315200 1:CAS:528: DC%2BD28XmsVagu74%3D (Pubitemid 44035547)
39. A Wells U Marti 2002 Signalling shortcuts: cell-surface receptors in the nucleus? Nat Rev Mol Cell Biol 3 697 702 12209129 10.1038/nrm905 1:CAS:528:DC%2BD38Xmslagu7w%3D (Pubitemid 34987790)
40. S Mikami K Katsube M Oya, et al. 2009 Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas J Pathol 218 530 539 19455604 10.1002/path.2567 1:CAS:528:DC%2BD1MXhtVSqu7%2FN
41. A Sasaki K Ishikawa N Haraguchi, et al. 2007 Receptor activator of nuclear factor-kappaB ligand (RANKL) expression in hepatocellular carcinoma with bone metastasis Ann Surg Oncol 14 1191 1199 17195907 10.1245/s10434-006-9277-4
42. FC Perez-Martinez V Alonso JL Sarasa, et al. 2008 Receptor activator of nuclear factor-kappaB ligand (RANKL) as a novel prognostic marker in prostate carcinoma Histol Histopathol 23 709 715 18366009 (Pubitemid 351552356)